Ketamine infusion therapy is used primarily for treatment-resistant depression, where two or more antidepressants have failed to produce adequate relief; major depressive disorder with acute suicidal ideation requiring rapid intervention; PTSD and anxiety disorders not responding to standard treatments; bipolar depression in carefully managed clinical contexts; OCD; and certain chronic pain conditions including fibromyalgia and complex regional pain syndrome. The rapid antidepressant mechanism through NMDA glutamate receptor blockade distinguishes ketamine infusion from all conventional antidepressants and accounts for its efficacy in treatment-resistant populations. Call 949-625-0564 to discuss whether ketamine infusion is appropriate for your diagnosis.

Ketamine infusion works by blocking NMDA glutamate receptors, which triggers downstream activation of AMPA receptors and release of BDNF, promoting rapid synaptogenesis in prefrontal and limbic circuits disrupted by depression. This cascade produces measurable antidepressant effects within hours by restoring neural connectivity in mood-regulating circuits rather than through the gradual receptor upregulation that conventional antidepressants require. The neuroplastic changes initiated by infusion continue after the acute ketamine effects fade, and each successive session in the series builds on the neuroplastic changes of prior sessions.

A standard ketamine infusion protocol for depression involves six infusions over two to three weeks as an initial course, typically administered three times per week in the first week and three more times in the second week. Each infusion lasts approximately 40 to 60 minutes plus monitoring time. Maintenance infusions following the initial course are scheduled at individualized intervals based on how long each patient maintains their improvement between sessions, ranging from monthly to several times per year. The exact protocol is adjusted by the clinical team based on clinical response.

Ketamine infusion uses racemic ketamine containing both S-ketamine and R-ketamine delivered intravenously, is used off-label for psychiatric indications, and is generally self-pay as insurance does not typically cover off-label use. Spravato contains only esketamine (S-ketamine) delivered as a nasal spray, has FDA approval for treatment-resistant depression and MDD with suicidal ideation, and is covered by most major insurers for qualifying patients. Both require clinical supervision and a driver home; Spravato requires the two-hour REMS monitoring period. The choice depends on diagnosis, clinical factors, and insurance coverage.

Contraindications to ketamine infusion include personal or family history of schizophrenia or primary psychotic disorders; uncontrolled cardiovascular disease or severely elevated blood pressure; active substance use disorders involving alcohol or dissociative drugs; pregnancy; and significantly elevated intracranial or intraocular pressure. These are identified through the comprehensive pre-treatment evaluation at Moment of Clarity. Active psychosis is the most significant contraindication as ketamine's dissociative properties can worsen psychotic symptoms.

Ketamine infusion compares to antidepressants in fundamentally different ways: speed of onset hours to days versus four to eight weeks; mechanism of action glutamate pathway versus serotonin pathway; administration scheduled infusions versus daily oral medication; and insurance coverage generally self-pay versus covered for most indications. For treatment-resistant patients who have failed multiple antidepressants, ketamine infusion provides a neurochemically distinct pathway with response rates significantly higher than continuing to try additional antidepressants. Research shows approximately 70% response rates among patients completing a full infusion course.

Ketamine infusion works remarkably rapidly, with many patients reporting meaningful mood improvements within hours of their first infusion and most responding within the first week of treatment. This rapid onset is the single most clinically important characteristic distinguishing ketamine from all other depression treatments and makes it particularly valuable for patients in acute distress, those with active suicidal ideation, or those who have spent months or years without adequate relief and cannot wait weeks for a conventional antidepressant to work.

During a ketamine infusion session at Moment of Clarity, you are settled in a comfortable monitored clinical setting and the infusion is administered intravenously over approximately 40 to 60 minutes by qualified medical staff. During the infusion you may experience mild dissociation, dizziness, altered perception, or a dreamlike quality that resolves within hours. Vital signs and clinical status are monitored throughout. After the infusion, you remain in the monitored setting for an additional period before being cleared to leave with your designated driver. Staff are available throughout for any questions or concerns.

IV ketamine infusion is generally not covered by standard insurance as it is used off-label for psychiatric indications. Most patients pay out of pocket for infusions. Spravato esketamine, by contrast, is FDA-approved and covered by most major insurers for qualifying patients. For patients with qualifying diagnoses who prefer a covered option, Spravato at Moment of Clarity may be the more financially accessible choice. Free insurance verification confirms your specific coverage for either option. Call 949-625-0564.

Starting ketamine infusion at Moment of Clarity begins with a free call to 949-625-0564. A clinical evaluation confirms candidacy and the team discusses cost, scheduling, and the option of Spravato as a covered alternative. Tustin and Oceanside locations offer ketamine-based treatment within comprehensive outpatient programs. Same-day consultations are available.